Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Aflibercept · Ahzantive, Eylea

Fusion protein · Inhibitor of Vascular endothelial growth factor A (VEGFA) and Placental growth factor (PGF) · developed by Regeneron Pharmaceuticals

Approved FDA, Nov 2011
1 Registered trials

What is Aflibercept?

Aflibercept is a soluble decoy receptor fusion protein that binds vascular endothelial growth factor A (VEGF-A) and placental growth factor (PlGF), inhibiting their binding and activation of VEGF receptors on endothelial cells. It is used in eye diseases involving abnormal blood vessel growth and leakage, and is studied in diabetic macular edema.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Ahzantive, Eylea, Eylea Hd, Pavblu
Drug type
Fusion protein
Targets
Vascular endothelial growth factor A (VEGFA), Placental growth factor (PGF), Vascular endothelial growth factor receptor 1 (FLT1) (binding partner it blocks), Vascular endothelial growth factor receptor 2 (KDR) (binding partner it blocks)
Mechanism
Inhibitor of Vascular endothelial growth factor A (VEGFA) and Placental growth factor (PGF)
Pathways
angiogenesis, vascular permeability
Therapy area
Ophthalmology
Developer
Regeneron Pharmaceuticals
In trials of
FDMT
FDA status
Approved as Ahzantive, Eylea, Eylea Hd (November 18, 2011), BLA125387 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Jul 7, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07867080 Phase 3 Diabetic Macular Edema (DME) Recruiting FDMT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetic Macular Edema (DME)

Other drugs acting on VEGFA / PGF

ABP 938 FDA approved Bevacizumab FDA approved Ivonescimab Phase 3 Pumitamig Phase 2/3 Tovecimig Phase 2/3

Sources

Updated Oct 11, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.